Clinical trial
A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin
NCT07215312 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- October 13, 2025
- Completion date
- December 31, 2026
- Enrollment
- 100 (estimated)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.